On Feb. 8, 2021, Repligen and Navigo Proteins announced that they had completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin, a novel affinity resin to be utilized in the purification of COVID-19 vaccines.

The availability of this COVID-19 affinity resin was the result of an accelerated program to provide COVID-19 vaccine manufacturers with a high purity capture step, decreasing processing time and significantly improving overall yield in the production of these critical vaccines.